1	Minding the margins: Evaluating the impact of COVID-19 among Latinx and Black
2	communities with optimal qualitative serological assessment tools
3	Raquel A. Binder ^{1¶*} , Angela M. Matta ^{1¶} , Catherine S. Forconi ¹ , Cliff I. Oduor ² , Prajakta
4	Bedekar ^{3,4} , Paul N. Patrone ³ , Anthony J. Kearsley ³ , Boaz Odwar ¹ , Jennifer Batista ⁵ ,
5	Sarah N. Forrester ⁵ , Heidi K. Leftwich ⁶ , Lisa A. Cavacini ¹ , Ann M. Moormann ¹
6	
7	[¶] Authors contributed equally
8	
9	¹ Department of Medicine, University of Massachusetts Chan Medical School,
10	Worcester, MA, USA
11	² Department of Pathology and Laboratory Medicine, Warren Alpert Medical School,
12	Brown University, Providence, RI, USA
13	³ Applied and Computational Mathematics Division, National Institute of Standards and
14	Technology, Gaithersburg, MD, USA
15	⁴ Department of Applied Mathematics and Statistics, Johns Hopkins University,
16	Baltimore, MD, USA
17	⁵ Department of Population and Quantitative Health Sciences, University of
18	Massachusetts Chan Medical School, Worcester, MA, USA
19	⁶ Department of Obstetrics and Gynecology, University of Massachusetts Chan Medical
20	School, Worcester, MA, USA
21	
22	*Corresponding author: E-mail: raquel.binder@umassmed.edu (RAB)
23	Running title: SARS-CoV-2 among Minorities and Methods

24 Abstract word count: 234

25 Main text word count: 3914

26

27 Abstract

COVID-19 disproportionately affected minorities, while research barriers to engage 28 29 underserved communities persist. Serological studies reveal infection and vaccination histories within these communities, however lack of consensus on downstream evaluation 30 methods impede meta-analyses and dampen the broader public health impact. To reveal 31 32 the impact of COVID-19 and vaccine uptake among diverse communities and to develop 33 rigorous serological downstream evaluation methods, we engaged racial and ethnic 34 minorities in Massachusetts in a cross-sectional study (April - July 2022), screened blood 35 and saliva for SARS-CoV-2 and human endemic coronavirus (hCoV) antibodies by beadbased multiplex assay and point-of-care (POC) test and developed across-plate 36 normalization and classification boundary methods for optimal qualitative serological 37 38 assessments. Among 290 participants, 91.4 % reported receiving at least one dose of a COVID-19 vaccine, while 41.7 % reported past SARS-CoV-2 infections, which was 39 40 confirmed by POC- and multiplex-based saliva and blood IgG seroprevalences. We found significant differences in antigen-specific IgA and IgG antibody outcomes and indication 41 of cross-reactivity with hCoV OC43. Finally, 26.5 % of participants reported lingering 42 43 COVID-19 symptoms, mostly middle-aged Latinas. Hence, prolonged COVID-19 symptoms were common among our underserved population and require public health 44 45 attention, despite high COVID-19 vaccine uptake. Saliva served as a less-invasive 46 sample-type for IgG-based serosurveys and hCoV cross-reactivity needed to be

47	evaluated for reliable SARS-CoV-2 serosurvey results. Using the developed rigorous
48	downstream qualitative serological assessment methods will help standardize serosurvey
49	outcomes and meta-analyses for future serosurveys beyond SARS-CoV-2.
- 0	

50

51 Key words: SARS-CoV-2, serosurvey, Luminex, saliva, Latino/Latinx/Hispanic, Black,

52 Massachusetts, across-plate normalization, serological threshold calculation methods.

53

54 Introduction

55 Differential health care access and exposure risks have led to racial and ethnic COVID-56 19 disparities in the United States (US), leaving Latinx and Black communities to 57 experience disproportionately high SARS-CoV-2 infection rates and COVID-19 related 58 morbidity and mortality.(1, 2) Seroprevalence studies have become essential public health tools to assess the regional spread and pre-existing immunity to SARS-CoV-2 59 among at-risk populations.(3-5) Further, by distinguishing between anti-SARS-CoV-2 60 61 spike (S), receptor-binding domain (RBD), and nucleocapsid (N) antibodies, COVID-19 62 vaccine uptake (RBD/S only) can be estimated and compared to past SARS-CoV-2 63 infections.(6) Anti-SARS-CoV-2 immunoglobulin (Ig)G and IgA antibodies can be measured in both blood and saliva, the latter serving as less invasive sample collection 64 65 alternative.(7)

Here, we engaged ethnic and racial minorities to evaluate the impact of COVID-19 in the Greater Worcester area from April to July of 2022 and evaluated blood- and salivabased serosurvey methods. Overall, this study (i) evaluated the impact of COVID-19 and vaccine uptake among marginalized communities, (ii) confirmed the utility of using saliva

for serosurveys, (iii) compared the utility of a bead-based multiplex assay vs. a point-ofcare (POC) test for SARS-CoV-2 antibody measurements, and (iv) demonstrated the benefit of developing and using classification boundary methods for optimal interpretation of serological assays.

74

75 Methods

76 Participant Recruitment and Sample Collection

77 This cross-sectional study was approved by the University of Massachusetts Chan 78 Medical School (UMass Chan) Institutional Review Board (IRB Docket # H00023083). 79 Structured interviews with Black and Latinx community members in the Greater 80 Worcester Area in Massachusetts (MA) were conducted to identify recruitment barriers 81 for participation in research and IRB-approved study flyers distributed prior to engagement with local stakeholders. We subsequently joined regular community 82 83 gatherings organized by Net of Compassion, Centro Hispano, and Central MA YMCA in 84 Worcester, along with the St. John Catholic Church in Clinton for in-person recruitment events implemented both in Spanish and English from April 21st to July 4th of 2022. On 85 86 site, we provided a fact sheet explaining the purpose of the study and were available to answer questions in Spanish and English. We obtained informed verbal consent from 87 88 eligible individuals (inclusion criteria: 18+ years of age, exclusion criteria: prisoners and 89 people unable to communicate in English or Spanish) and participants were asked to fill out a brief RedCap survey covering demographic information, COVID-19 vaccine, and 90 91 SARS-CoV-2 infection history through tablets that were provided by the study team or by 92 QR codes that could be scanned on personal devices. We used verbal (not written)

93 consent for this minimal risk study due to hesitation of documentation and decreased literacy rate among individuals from underserved communities. The verbal consent was 94 95 documented by the research team member interviewing the participant and this method 96 was approved by the IRB prior to study begin. Subsequently, blood and saliva samples 97 were collected with Tasso SST devices (Tasso, Inc., Seattle, WA) and SuperSal2[®] 98 devices (Oasis Diagnostics, Vancouver, WA), respectively, as per manufacturer's 99 guidelines. SARS-CoV-2 anti-immunoglobulin (Ig)G and IgM antibodies were detected 100 with an emergency use authorized approved POC test (FaStep from Assure Tech, 101 Hangzhou, China) and results provided to participants, along with a \$50 reimbursement.

102 See Supplemental Methods for more information on sample collection and processing.

103 Multiplex Luminex Assay

104 The following SARS-CoV-2 antigens were coupled to Luminex MagPlex Microspheres as 105 indicated by the manufacturer: Wild-type (WT; Wuhan) full-length spike (S), WT nucleocapsid (N), WT receptor-binding domain (RBD), RBD alpha, RBD beta, RBD 106 107 gamma, RBD delta, RBD lambda, and RBD omicron. Following human endemic 108 coronavirus (hCoV) antigens and a Bovine Serum Albumin (BSA) control were coupled: 109 HKU1, OC43, NL63, and 229E, see Supplemental Methods for more details. Briefly, after 110 validation of conjugated beads, the participant samples were screened on 96- or 384-111 well plates, including a seven- or ten-point serial dilution standard. Conjugated beads 112 covering the antigen panel were combined and washed, incubated, washed again, and 113 biotinylated anti-human secondary IgG or IgA (BD Pharmingen) antibody added. After 114 incubation and washing, phycoerythrin conjugated streptavidin was added (BD 115 Pharmingen). Finally, after incubation, washing, and resuspension, the plate was

screened by a FlexMap 3D Luminex instrument. The antigen-specific median fluorescence intensity (MFI) for each sample was recorded and BSA subtracted (including for the standards) to account for non-specific bead binding.(8) Saliva samples were screened for total IgG and total IgA antibodies to account for differential salivation flow rates by coupling anti-human IgG gamma chain (Bio-Rad, Hercules, CA) and anti-human IgA alpha chain protein (Abcam, Cambridge, UK) respectively.

Previously described de-identified banked blood samples served as positive (n=50) and negative blood controls (n=50).(9) Banked saliva samples (n=50), collected with the same SuperSal2 devices, served as alternative control group for the seroprevalence calculation, see qualitative serological assessments below.

126 Across-plate Normalization

Dilution series of standards for each antigen-plate combination were weighted using a plate-dependent variance while a normalization factor was computed with custom MATLAB scripts. This factor was then applied by multiplying it with each antigen/isotypespecific sample MFI on the plate, see Supplemental Methods for more details.

131 Qualitative Serological Assessments

Sample MFIs were translated to qualitative (i.e., binary positive/negative) outcomes as described in reference (10) and in the Supplemental Methods. Briefly, for the <u>blood</u> samples, empirical training data were taken as approximate probability models of measurement outcomes for each antigen, conditioned on knowing the class of the underlying sample. The analysis was applied to multidimensional data by treating up to three antigens as distinct axes in a coordinate space, see **S1 Figure** for a threedimensional analysis example. Due to the lack of collection method- and population-

matched controls, the <u>saliva</u>-based IgG seroprevalence calculations were determined
with alternative control samples from a 2020 Kenyan study (proxy for negative training
data), see Supplemental Methods for more details.

142 Statistical analysis

Statistical calculations and graphs were done in Prism v9.4.1, R v2023.09.1+494,
MATLAB R2023a Update 5 (9.14.0.2337262).

145

146 **Results**

147 Demographics and Vaccine/Infection History

148 A total of 290 adult study participants were enrolled in Worcester, Shrewsbury, and 149 Clinton, MA between April and July of 2022. Most participants donated blood (98.6 %, 150 n=286) and saliva (94.8%, n=275) samples. Participants who did not give a saliva sample 151 mostly lacked saliva production (i.e., dry mouth), especially among elderly, but were not 152 hesitant to donate the sample. The demographic, clinical, and SARS-CoV-2 infection 153 history survey was filled out by 98.3 % participants (n=285), while 47.6 % (n=138) chose 154 to answer in Spanish and 51.7 % (n=150) in English (see Supplemental Materials for full 155 survey). Most participants self-identified as Latinx/Hispanic (67.6 %, n=196), and female (61.0 %, n=177), while the average age was 45 years (range: 18-82, STDV: 16.3), and 156 31.4 % (n=91) of participants received a college or higher education degree, see Table 157 158 **1**. Non-Hispanic White participants constituted 13.4 % (n=39) of the study population. 159 Among the participants, 15.5 % (n=45) reported pre-existing health conditions, most 160 commonly hypertension, obesity, diabetes type II, and asthma, while 13.5 % (n=39) 161 reported smoking or vaping prior to the pandemic, see **S1 Table**.

162

Table 1. Study participant demographics from 290 study participants enrolled in Massachusetts from April to July 2022 and 286 associated blood samples collected during the study period.

		Nucleocapsid	Nucleocapsid	
		IgG Positive	lgG Negative	χ^2
	Overall	Serum	Serum	λ
	n (%)	n (%)	n (%)	p-value ³
Total	290 (100)	136 (49.9±7) [#]	150 (52.5)	
Age (years)				
18-40	126 (43.5)	52 (38.2)	72 (48.0)	0.292
41-60	96 (33.1)	45 (33.1)	51 (34.0)	
>60	59 (20.3)	31 (22.8)	26 (17.3)	
Missing	9 (3.1)	8 (5.9)	1 (0.7)	
Gender				
Female	177 (61.0)	79 (58.1)	96 (64.0)	0.393
Male	109 (37.6)	54 (39.7)	53 (35.3)	
Non-binary	3 (1.0)	2 (1.5)	1 (0.7)	
Missing	1 (0.4)	1 (0.7)	0 (0.0)	
Race				
White	97 (33.5)	39 (28.7)	56 (37.3)	0.039*
Mixed/Mestizo	90 (31.0)	53 (39.0)	37 (24.7)	
Black/African American	29 (10.0)	14 (10.3)	15 (10.0)	
Asian	31 (10.7)	9 (6.6)	21 (14.0)	
Other	43 (14.8)	21 (15.4)	21 (14.0)	
Ethnicity				
Hispanic	196 (67.6)	104 (76.5)	90 (60.0)	0.0013**
non-Hispanic	91 (31.4)	29 (21.3)	60 (40.0)	
Missing	3 (1.0)	3 (2.2)	0 (0.0)	
Education				
High School or less	100 (34.5)	57 (41.9)	40 (26.7)	0.0193*
College or more	91 (31.4)	37 (27.2)	54 (36.0)	
Missing	99 (34.1)	42 (30.9)	56 (37.3)	

SARS-CoV-2 + Test				
Yes	121 (41.7)	71 (52.2)	49 (32.7)	0.0003***
No	163 (56.2)	59 (43.4)	101 (67.3)	
Missing	6 (2.1)	6 (4.4)	0 (0.0)	
Fully Recovered $^{\phi}$				
Yes	108 (37.2)	54 (39.7)	53 (35.3)	0.0099**
No	21 (7.2)	18 (13.3)	3 (2.0)	
Long COVID	19 (6.6)	12 (8.8)	7 (4.7)	
Never had COVID	136 (46.9)	46 (33.8)	87 (58.0)	
Missing	6 (2.1)	6 (4.4)	0 (0.0)	

167

¹⁶⁸ [•]The "Missing" categories, the "Non-binary" category in gender, and the "Never had COVID"

169 category under "Fully Recovered" were omitted for the χ^2 test comparison; p-value < 0.05. The

170 gender, ethnicity, education, and SARS-CoV-2 test comparison were done with the Fisher's

171 exact test (2x2 categories). * p-value < 0.05, ** p-value < 0.01, ***p-value < 0.001.

[#]136 is the empirical count of positives (equal to a 47.5 % empirical seroprevalence) and 49.9 %
(95% CI: ±7) is the calculated bias-corrected seroprevalence.

¹⁷⁴ [•]COVID-19 recovery among all study participants (including 121 test-confirmed cases). Self-

175 reporting having fully recovered from a SARS-CoV-2 infections ("Yes") or not ("No"), whether

176 infection-associated symptoms lasted past 4 weeks of the initial infection and therefore reported

177 long COVID-19 symptoms (Long COVID), and those who never had COVID-19 (Never had

178 COVID). For the χ^2 test comparison the "Missing" and the "Never had COVID" categories were 179 omitted.

180

181 A total of 265 (91.4 %) participants received at least one dose of a COVID-19 182 vaccine; 45.7 % (n=121) Moderna; 40.0 % (n=106) Pfizer; 8.6 % (n=23) Johnson and 183 Johnson; and 5.7 % (n=15) 'other', for the base vaccine series, see **S1 Table.** The vaccine 184 uptake was lower for the second dose (84.5 %, n=245) and booster (68.3 %, n=198) while 185 most participants received an influenza vaccine in the past 5 years (79.3 %, n=230). As 186 for vaccine-related side effects, 37.7 % (n=100), 43.7 % (n=107), and 35.9 % (n=71) of 187 participants did not experience any post-COVID-19 vaccine symptoms post-first dose, second dose and -booster, respectively. Among those who experienced vaccine-188 189 associated symptoms post-base vaccine series and booster, the average severity scores

190 were 4.1 (STDV: 2.4; range: 1-10) and 3.6 (STDV: 2.2; range:1-10) respectively on a 191 scale from 1 to 10, while arm soreness, fever, and fatigue were the most frequently 192 reported symptoms. Further, 16.6 % (n=44), 14.7 % (n=36), and 6.1 % (n=12) of 193 participants experienced severe symptoms (rating ≥ 6) post-first dose, second dose, and 194 booster, respectively, encompassing thrombosis, strokes, fainting, and migraines. A total 195 of 6 participants reported vaccine-associated hospitalizations, encompassing all doses 196 for all participants. Among those who were not vaccinated, participants reported being 197 hesitant because of fear of COVID-19 vaccine side effects, lack of trust in the vaccine, 198 and not knowing enough about the vaccine.

199 A total of 121 (41.7 %) participants reported testing positive for SARS-CoV-2 at 200 least once and the associated average symptom severity score was 5.4 (STDV: 2.4; 201 range: 1-10), while 43.0 % (n=52) experienced severe symptoms (rating \geq 6) and 9.1 % 202 (n=11) were hospitalized. The most common symptoms were body aches (52.1 %, n=63), 203 fever (51.2 %, n=62), fatigue (51.2 %, n=62), cough (48.8 %, n=59), headache (46.3 %, 204 n=56), sore throat (45.5 %, n=55), congestion/runny nose (38.0 %, n=46), and loss of 205 smell or taste (36.4 %, n=44). A total of 7 individuals (5.8 %) reported not having any 206 symptoms associated with the positive test (i.e., asymptomatic infections). There was an 207 association between reporting pre-existing health conditions and elevated severity scores (rating \geq 6. Fisher's exact test, p=0.0475) but not between smoking/vaping and elevated 208 209 severity scores (rating \geq 6, Fisher's exact test, p=>0.999). Among those with confirmed 210 SARS-CoV-2 infections (n=121), 26.5 % (n=32) reported not having fully recovered from 211 the infection and 14.1 % (n=17) reported long COVID-19 symptoms (persistent symptoms) 212 past 4 weeks of diagnosis). For further analysis, the categories "not fully recovered from

213 the infection" and reporting "long COVID-19 symptoms" were collapsed. Within this 214 category, 78.1 % (n=25) were female, 87.5 % (n=28) were Latinx, 59.4 % (n=19) of 215 mixed/mestizo race, and the average age was 48.6 years (STDV: 16.4, range: 19-82). 216 There was a significant association between being 50+ years of age and not having fully 217 recovered from COVID-19 symptoms (Fisher's exact test, p=0.0135). There was no 218 significant correlation between being female or reporting pre-existing health conditions 219 and not having recovered from COVID-19 symptoms. Since the majority of the study population self-identified as Latinx and/or belonging to racial minorities, we were not able 220 to contrast unresolved COVID-19 symptoms or any other variables among racial/ethnic 221 222 sub-groups.

223 Blood-based SARS-CoV-2 Antibodies

224 Among those who received a SARS-CoV-2 POC antibody results (n=284), 93.7 % 225 (n=266) were positive for IgG and 4.6 % (n=13) for IgM. The POC test covered both 226 SARS-CoV-2 N and S antigens, while the multiplex assay allowed measuring presence 227 of antibodies based on individual antigens and therefore distinguish between vaccine-228 (S/RBD-only since all currently FDA-approved COVID-19 vaccines in the US are S/RBD-229 based and do not include the N antigen) and infection-induced antibodies. The serum 230 multiplex-based IgG seroprevalences resulted in 97.5 % ± 2.4 % (95 % CI) for RBD/S/N 231 (3 antigens), 99.9 % ± 3.4 % (95 % CI) for RBD/S (2 antigens), 97.2 % ± 2.0 % (95 % CI) for S/N (2 antigens), 96.5 % ± 2.2 % (95 % CI) for RBD/N (2 antigens), 96.5 % ± 2.2 % 232 233 (95 % CI) for RBD, and 97.9 % ± 1.7% (95 % CI) for S (see S2 Table), mirroring the high 234 self-reported vaccination uptake. The serum-based IgG N seroprevalence was 49.9 % ± 235 7.0 % (95% CI), indicating past infection rather than vaccination and mirrored self-

236 reported exposures. Statistically significant differences in N-specific serological test 237 outcomes were observed among study participants based on race, ethnicity, education, 238 and having fully recovered from COVID-19 symptom, as well as based on self-reported 239 SARS-CoV-2 test results prior to study participation, see **Table 1**. The S- and RBD-240 specific serological test outcomes were not contrasted based on the listed categories due 241 to the high overall seroprevalence and self-reported vaccine uptake being close to 100 242 %. As for SARS-CoV-2 variants, the delta variant had the most abundant antibodies 243 among our study population, see Fig 1.

244

Fig 1. Serum IgG Outcome Distribution. Dot plot with means and 95% confidence
intervals (CI) of antigen-specific outcomes (MFI - BSA) for serum IgG, covering SARSCoV-2 (including variants) and human endemic coronaviruses (OC43, HKU1, NL63,
229E) with log10 y-axis. See Supplemental Figure 11 for plots with linear y-axis. MFI,
median fluorescence intensity. N, Nucleocapsid. S, Spike. RBD, Receptor Binding
Protein. hCoV, human endemic coronaviruses. WT, wild-type (Wuhan).

251

The concordance between the POC test results and qualitative multiplex assay outcomes was high. While the multiplex assay was more likely to pick up a positive outcome, 94.0 % (267/284) of the outcomes aligned between the POC test and the RBD/S/N (3 antigen) analysis (i.e.,17 outcomes did not match: 14 were positive by multiplex but negative by POC, and 3 were negative by multiplex but positive by POC). Similarly, 94.4 % (268/284) of the outcomes aligned between POC and the S/N (2 antigen) analysis, 94.4 % (268/284) of the outcomes aligned between POC and the S/N (2

RBD/N (2 antigen) analysis, and 93.7 % (266/284) of the outcomes aligned between POC and the RBD/S (2 antigen) analysis. Comparing the POC outcomes with antigen specific MFIs revealed a correlation between a positive POC test and increasing MFI multiplex assay measurements for S and RBD, but not for N (see Fig 2), indicating that the POC test was reliably detecting the RBD/S antibodies measured by the multiplex assay.

264

265 Fig 2. Antigen-specific median fluorescence intensity read out broken down by 266 point-of-care test outcome. Comparing the point-of-care test outcome (POC) 267 outcomes with antigen specific median fluorescence intensity (MFIs) revealed a 268 correlation between a positive POC test and increasing MFI multiplex measurements 269 for (A) S (ns, p=0.06) and (B) RBD, but not for (C) N (ns, p=0.19, p=0.06, p=0.86). MFI, 270 median fluorescence intensity. N, Nucleocapsid. S, Spike. RBD, Receptor Binding 271 Protein. POC, point-of-care test result. (-), POC negative. (+), POC positive (light band). (++), POC positive (dark band). Ns, non-significant ($p \ge 0.05$). *** = p < 0.001. **** = 272 273 p<0.0001.

274

To analyze the potential cross-reactivity between SARS-CoV-2 and hCoVs, we evaluated IgG OC43, HKU1, 229E, and NL63 antibody levels in the blood samples. Anti-OC43 and anti-229E were the most abundant antibodies among our study population, see **Fig 1**. Given that OC43 is closely related to SARS-CoV-2 (both β -CoV members) (11), we compared SARS-CoV-2 and OC43 antibody measurements (both S-based) and found the correlation to be low (R² = 0.2), see **Fig 3**. Still, the antibody measurements for both were high, see **Fig 1**, and a paired t-test did not find the paired OC43 and SARS-

282 CoV-2 measurements to be significantly different, see Fig 3. Hence, cross-reactivity 283 between IgG S measurements for SARS-CoV-2 and OC43 could not be ruled out. We 284 further analyzed the samples that were non-concordant between the multiplex analysis 285 and the POC test for cross-reactivity (i.e., samples that were positive for the multiplex 286 assay and negative for the POC test across all antigen combinations). The average 287 SARS-CoV-2 S MFI of the non-concordant samples (n=15) was lower compared to the 288 concordant samples (n=265), but the S-based OC43 measurements were not significantly higher (see S2 Figure), indicating that the multiplex assay was more sensitive compared 289 290 to the POC test but not more likely to pick up OC43. Note that the statistical outcomes 291 may be affected by the unequal sample sizes (15 vs 265).

292

Fig 3. Comparison of SARS-CoV-2 and OC43 antibody measurements. (A) There was no/low correlation ($R^2 = 0.2$) between SARS-CoV-2 and OC43 S-based MFI, both Spike [S]-based MFI. (B) Still, the paired antibody measurements for OC43 and SARS-CoV-2 were not significantly different by paired t test (p=0.84). Hence, cross-reactivity between IgG S measurements for SARS-CoV-2 and OC43 could not be ruled out. MFI, median fluorescence intensity. Ns, non-significant (p \ge 0.05).

299

While anti-SARS-CoV-2 IgA has been shown to resolve faster than IgG, mucosal and blood-based IgA may provide protection from infections.(7, 12-14) Hence, we measured serum-based *IgA* seroprevalence which resulted in 87.2% \pm 6.4% (95% CI) for RBD/S/N (3 antigens), 83.1 % \pm 6.7 % (95 % CI) for RBD/S (2 antigens), 84.8 % \pm 6.6 % (95 % CI) for S/N (2 antigens), 39.8 % \pm 12.2 % (95 % CI) for RBD/N (2 antigens), 62.7

 $\% \pm 14.5 \%$ (95 % CI) for RBD, 84.0 % $\pm 6.7 \%$ (95 % CI) for S, and 14.1 % $\pm 25.5 \%$ (95 % CI) for N, see **S3 Table**. Comparing the antigen-specific outcomes in blood resulted in significantly lower MFIs for IgA compared to IgG for all antigens (p<0.0001; Welch's t test), see **S3, S4,** and **S5 Fig**.

309 Saliva SARS-CoV-2 Antibodies

310 The saliva-based IgG seroprevalences and uncertainty range (approximating the 311 100 % confidence interval) resulted in 100.0 % (98.7 – 100.0) for RBD/S/N (3 antigens), 312 100.0 % (98.7 – 100.0) for RBD/S (2 antigens), 96.0 % (92.4 – 99.6) for S/N (2 antigens), 313 86.9 % (81.6 – 96.4) for RBD/N (2 antigens), 86.9 % (75.8 – 96.2) for RBD, 96.0 % (92.4 314 - 99.6) for S, and 48.0 % (48.0 - 99.7) for N, see S4 Table. The SARS-CoV-2 315 seroprevalences from saliva and serum resulted in comparable outcomes for IgG (see S2 316 and **S4 Tables**), and the concordance between the gualitative positive/negative antibody 317 results was high; 97.6 % (279/286) of the results aligned for the IgG RBD/S/N (3 antigen) 318 analysis (i.e., 7 participants had positive saliva samples but negative blood samples by 319 IgG RBD/S/N multiplex analysis). Note that the concordance reflects the underlying high 320 overall seroprevalence. A direct comparison of saliva and blood MFIs was not possible 321 since saliva antibody measurements (MFI minus BSA, divided by total Ig, and multiplied 322 by 1000) were transformed differently than blood/serum (MFI minus BSA) to account for 323 variation in salivary flow rates and comparing the differently transformed MFIs between 324 serum and saliva for each SARS-CoV-2 antigen did not identify a correlation, see S6 Fig. 325 The saliva-based IgA seroprevalences could not be calculated because the 326 antigen-specific outcomes (transformed MFIs) between the study participant and 327 alternative control samples overlapped significantly, see S7 Fig. Hence, no classification

boundaries and therefore no percent seroprevalence could be established. However, comparing the antigen-specific measurements (MFI) in saliva resulted in significantly lower reads for IgA compared to IgG for the RBD and S antigen outcomes (p<0.0001; Welch's t test), see **S8 and S9 Fig.** Whereas for the N-specific outcomes in saliva, there were less overall antibodies (e.g., lower transformed MFIs compared to RBD and S), and the IgA reads were significantly higher compared to IgG, see **S10 Fig**.

334

335 Discussion

336 This study outlines an effective culturally sensitive recruitment method that overcame 337 research study access barriers generally reported among US minority populations, 338 enrolling 290 participants within four months. (2, 15-17) Among the mostly Latinx young 339 to middle aged peri-urban MA study population, the majority reported being vaccinated 340 (91.4 %), which was confirmed by blood and saliva IgG screening. According to the MA 341 Department of Public Health, 86.9 % of the MA population had received at least one dose 342 of a COVID-19 vaccine by July 2022(18) and 81.4 % of the general US population had 343 received at least one COVID-19 vaccine dose by May 2023.(19) Hence, our diverse study 344 population had a high vaccine uptake and did not reflect the reported vaccine hesitancy among minorities.(16, 17, 20) This may have been due to widely available COVID-19 345 vaccines in MA as vaccine availability and general ease of access has been cited as one 346 347 of the main uptake barriers among marginalized groups. (16, 17)

The self-reported infection history was mirrored by the N-based IgG seroprevalence outcomes in serum (N: 49.9 %) and saliva (N: 48.0 %). Hence, within two years and four months (the first COVID-19 case in MA was confirmed on Feb 1st 2022

351 (21) and the study recruitment ended in July of 2022) about half our diverse study 352 population had been exposed to SARS-CoV-2. Further, the reported average severity 353 scores were higher for infections (5.4) as compared to vaccination (4.1 and 3.6 for 354 baseline doses and booster, respectively) and the overall the number of vaccine-355 associated hospitalizations were lower (n=6) compared to infection-associated 356 hospitalizations (n=11). Additionally, 26.5 % of individuals who reported past infections 357 had not fully recovered and 14.1 % reported long COVID-19 symptoms. Among those 358 who experienced lingering COVID-19 symptoms, most were female (78.1%), Latinx (87.5 359 %) (n=28), and from mixed/mestizo race 59.4 % (n=19), while the average age was 48.6 360 years. Hence, indicating that long-term COVID-19 symptoms were prevalent among our 361 community-based study population. Our results were consistent with previous studies that 362 reported being 50+ years old and being from disadvantaged ethnic and socioeconomic 363 groups as a risk factor, although and comorbidities did not correlate with lack of COVID-364 19 symptom resolution, which could have been due to our small sample size of 365 participants with lingering COVID-19 symptoms.(22)

Finding high concordance (93.7 %) between the POC results and the RBD/S (2 366 367 antigen excluding N) analysis for IgG outcomes in blood and a correlation between a 368 positive POC test and increasing MFI multiplex measurements for IgG S and RBD (but 369 not for N) in blood indicated that the RBD and S measurements (more so than N) were 370 driving the overlapping results between the POC and multiplex outcome in our study 371 population. Our and other studies have found N-based antibody levels to be lower and 372 more variable (i.e., shorter half-life than S/RBD).(23, 24) Hence, while we found that the 373 POC test was an easy to use and reliable IgG vaccine-induced antibody measurement

tool, the multiplex assay was more sensitive and is more appropriate for serosurveys
 targeting and differentiating between infection- and vaccine-induced antibodies.

While the majority of SARS-CoV-2 serosurveys do not account for cross-reactivity between SARS-CoV-2 and hCoV measurements, we found that readout overlap for S between SARS-CoV-2 and OC43 could not be ruled out in our setting, indicating the need for further scrutiny in future serosurveys. This is particularly true as most individuals are thought to seroconvert for hCoVs during childhood (25-27) and variation in hCoV infection history has been proposed to induce protective immunity from COVID-19.(27-29)

382 In terms of methods, a current major challenge of serological analytics is (i) the 383 application of validated across-plate normalization methods to pool outcomes from a large 384 sample size, and (ii) the determination of threshold values to reliably convert quantitative 385 (MFIs) outcomes into gualitative (positive/negative) results.(9) We therefore validated a 386 weighted-standard curve across-plate normalization method and two classification 387 boundary methods for optimal qualitative serological assessments (one based on 388 predefined positive and negative controls and one based on an alternate control group), 389 across two isotypes (IgG and IgA) and two sample types (serum and saliva) As shown in 390 the results, applying our methods resulted in the alignment of survey answers, POC 391 results, and IgG-based serological outcomes with high classification accuracy, sensitivity 392 and specificity in serum and saliva for almost all antigen combinations.

393 Specific to saliva-based serological analytics, (i) variation in salivary flow rate due 394 to changes in circadian rhythm, stress, and sample collection method(30), and (ii) across 395 sample variation in isotype specific-outcomes (IgA and IgG) due to inherent biological 396 mechanisms (i.e., antibody source and half-life) are a major challenge.(31-33) Further, it

397 is problematic to pool saliva-based serological outcomes across studies and identify 398 appropriate controls since different saliva collection methods influence the composition 399 and guality of the collected samples. (34) Here, we compared multiplex-based anti-SARS-400 CoV-2 IgG and IgA antibody measurements in matched serum and saliva samples. Our 401 IgG-based serological outcomes in serum and saliva aligned, supporting the use of saliva 402 as a less-invasive and accessible sample particularly among hesitant research 403 participants. However, we found significant differences in antigen-specific IgA vs. IgG 404 antibody levels, similarly to previous reports.(7, 35) This was likely because (i) the half-405 life of IqA is shorter compared to IqG, and (ii) mucosal and systemic IqA production are 406 not synchronized.(7, 31, 33, 35) Further, the antigen-specific outcomes (MFI minus BSA 407 for serum and transformed MFI for saliva) between serum and saliva did not correlate, 408 even though the antigen-specific IgG seroprevalences aligned, underlining the 409 importance of including appropriate controls and threshold calculation methods for final 410 outcome comparisons.

The main limitation of our study was the restricted sample size. Hence, while our results generally align with previously published data, the statistical analyses and comparisons among infected individuals need to be confirmed among larger diverse populations. Further, most of our population carried anti-SAR-CoV-2 antibodies so subsequent statistical comparisons were restricted by the lack of negative outcomes.

In summary, this study successfully engaged marginalized MA communities and evaluated the impact of COVID-19 and vaccine uptake by implementing culturally sensitive recruitment methods and by giving appropriate study participant compensation in the form of immediate antibody results and adequate time and travel reimbursements.

420 We found a high vaccine uptake, and that about half of the participants were infected with 421 SARS-CoV-2 within 2+ years of the beginning of the pandemic. We found that lingering 422 COVID-19 symptoms were prevalent and impacted mostly middle-aged female Latinas. 423 indicating continued need for public health attention despite high COVID-19 vaccine 424 uptake. By comparison of matched blood and saliva samples, we found that saliva served 425 as a reliable non-invasive alternative for IgG but not IgA antibody measurements, and we 426 successfully adapted across plate normalization and classification boundary methods for optimal qualitative serological assessments. We also found that the bead-based multiplex 427 428 assay was more sensitive and better suited for serosurveys targeting infection- and 429 vaccine-induced antibodies compared to the less labor-intensive POC test and that hCoV 430 cross-reactivity should be evaluated for reliable SARS-CoV-2 serosurvey results.

431

432 Acknowledgement

433 We thank the study participants and their families for giving us their valuable time and 434 attention, they are the core of this study. We thank Centro Inc. (Centro las Americas) in 435 Worcester, MA, Dr. Juan A. Gomez, and the amazing team on the ground for partnering 436 with us on this study. We thank Pamela Suprenant from the Central MA YMCA, Pastors Richard (Richie) and Elizabeth Gonzalez from Net of Compassion, the Parish of Saint 437 438 John the Guardian of Our Lady in Clinton, MA and their welcoming congregation, and the 439 UMass Chan iCELS team for inviting us to recruit and engage their communities. This 440 study would not have been possible without the essential support of these individuals and 441 their institutions. Use of data in this manuscript was approved by the NIST Research 442 Protections Office under study number ITL-2020-0257. Certain commercial equipment,

443	instruments, software, or materials are identified herein to specify the experimental			
444	procedure. Such identification does not imply recommendation or endorsement by NIST			
445	nor does it imply that the materials or equipment identified are necessarily the best			
446	available for the purpose.			
447				
448	Financial Support			
449	This work was supported through the National Institutes of Health, NCI Serological			
450	Sciences Network (U01 CA261276), UMass Chan COVID-19 pandemic research fund,			
451	MassCPR Evergrande Award, and the National Center for Advancing Translational			
452	Sciences, National Institutes of Health, through Grant KL2-TR001455. The content is			
453	solely the responsibility of the authors and does not necessarily represent the official			
454	views of the NIH.			
455				
456	Conflicts of interests			
457	None of the authors declare a conflict of interest.			
458				
459	References			
460	1. Kullar R, Marcelin JR, Swartz TH, Piggott DA, Macias Gil R, Mathew TA, et al.			
461	Racial Disparity of Coronavirus Disease 2019 in African American Communities. J Infect			
462	Dis. 2020;222(6):890-3.			
463	2. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and			
464	Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A			
465	Systematic Review. Ann Intern Med. 2021;174(3):362-73.			

466 3. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al.

467 Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with

468 uncertainty from serological surveys. Elife. 2021;10.

469 4. Farnsworth CW, Anderson NW. SARS-CoV-2 Serology: Much Hype, Little Data.

470 Clin Chem. 2020;66(7):875-7.

5. CDC. Interim Guidelines for COVID-19 Antibody Testing 2022 [Available from:

472 https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-

473 guidelines.html.

474 6. Jones JM, Stone M, Sulaeman H, Fink RV, Dave H, Levy ME, et al. Estimated

475 US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood

476 Donations, July 2020-May 2021. JAMA. 2021;326(14):1400-9.

477 7. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of

478 serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19

479 patients. Sci Immunol. 2020;5(52).

480 8. Pickering JW, Larson MT, Martins TB, Copple SS, Hill HR. Elimination of false-

481 positive results in a luminex assay for pneumococcal antibodies. Clin Vaccine Immunol.

482 2010;17(1):185-9.

483 9. Binder RA, Fujimori GF, Forconi CS, Reed GW, Silva LS, Lakshmi PS, et al.

484 SARS-CoV-2 Serosurveys: How antigen, isotype and threshold choices affect the
485 outcome. J Infect Dis. 2022.

486 10. Patrone PN, Binder RA, Forconi CS, Moormann AM, Kearsley AJ. Minimal

487 Assumptions for Optimal Serology Classification: Theory and Implications for

488 Multidimensional Settings and Impure Training Data. arXiv. 2023.

- 489 11. Ding X. Liu JQL, and To S. Fung. Human Coronavirus-229E, -OC43, -NL63, and
 490 -HKU1 (Coronaviridae). Encyclopedia of Virology2021.
- 491 12. Takamatsu Y, Omata K, Shimizu Y, Kinoshita-Iwamoto N, Terada M, Suzuki T, et
- 492 al. SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and
- diminishes faster compared to IgG response. bioRxiv. 2022.
- 494 13. Vata A, Anita A, Manciuc CD, Savuta G, Luca CM, Rosu FM, et al. Clinical
- 495 significance of early IgA anti-SARS-CoV-2 antibody detection in patients from a
- 496 Romanian referral COVID-19 hospital. Exp Ther Med. 2022;23(6):391.
- 497 14. Montague BT, Wipperman MF, Chio E, Crow R, Hooper AT, O'Brien MP, et al.
- 498 Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk
- 499 first responders. Sci Rep. 2022;12(1):14932.
- 500 15. Paskett ED, Reeves KW, McLaughlin JM, Katz ML, McAlearney AS, Ruffin MT,
- 501 et al. Recruitment of minority and underserved populations in the United States: the
- 502 Centers for Population Health and Health Disparities experience. Contemp Clin Trials.
- 503 2008;29(6):847-61.
- 504 16. Corbie-Smith G. Vaccine Hesitancy Is a Scapegoat for Structural Racism. JAMA
 505 Health Forum. 2021;2(3):e210434.
- 506 17. Quinn SC, Andrasik MP. Addressing Vaccine Hesitancy in BIPOC Communities -
- 507 Toward Trustworthiness, Partnership, and Reciprocity. N Engl J Med. 2021;385(2):97-
- 508 100.
- 509 18. Daily COVID-19 Vaccine Report [Internet]. 2022. Available from: chrome-
- 510 extension://efaidnbmnnnibpcajpcglclefindmkaj/<u>https://www.mass.gov/doc/daily-covid-</u>
- 511 <u>19-vaccine-report-july-1-2022/download</u>.

- 512 19. COVID Data Tracker [Internet]. 2023. Available from: https://covid.cdc.gov/covid-
- 513 data-tracker/#vaccinations vacc-people-booster-percent-pop5.
- 514 20. Fisher C, Bragard E, Madhivanan P. COVID-19 Vaccine Hesitancy among
- 515 Economically Marginalized Hispanic Parents of Children under Five Years in the United
- 516 States. Vaccines (Basel). 2023;11(3).
- 517 21. Burke M. Coronavirus case in Boston is 1st in Massachusetts; 8th in the U.S.
- 518 NBC News. 2020.
- 519 22. Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID:
- 520 pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metab.
- 521 2023;34(6):321-44.
- 522 23. Whitcombe AL, McGregor R, Craigie A, James A, Charlewood R, Lorenz N, et al.
- 523 Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clin
- 524 Transl Immunology. 2021;10(3):e1261.
- 525 24. Vogelzang EH, Loeff FC, Derksen NIL, Kruithof S, Ooijevaar-de Heer P, van
- 526 Mierlo G, et al. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics
- 527 of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with
- 528 COVID-19. J Immunol. 2020;205(12):3491-9.
- 529 25. Dijkman R, Jebbink MF, Gaunt E, Rossen JW, Templeton KE, Kuijpers TW, et al.
- 530 The dominance of human coronavirus OC43 and NL63 infections in infants. J Clin Virol.
- 531 2012;53(2):135-9.
- 532 26. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic
- 533 Human Coronaviruses. Adv Virus Res. 2018;100:163-88.

534	27.	Li P, Ikram A, Peppelenbosch MP, Ma Z, Pan Q. Systematically Mapping Clinical
535	Feat	ures of Infections With Classical Endemic Human Coronaviruses. Clin Infect Dis.
536	2021	;73(3):554-5.

537 28. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic

538 coronavirus infection is associated with less-severe COVID-19. J Clin Invest.

539 2021;131(1).

540 29. Tsinda EK, Mmbando GS. Recent updates on the possible reasons for the low

541 incidence and morbidity of COVID-19 cases in Africa. Bull Natl Res Cent.

542 2021;45(1):133.

543 30. Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al. SARS-

544 CoV-2 vaccination induces mucosal antibody responses in previously infected

545 individuals. Nat Commun. 2022;13(1):5135.

546 31. van Tetering G, Evers M, Chan C, Stip M, Leusen J. Fc Engineering Strategies to

547 Advance IgA Antibodies as Therapeutic Agents. Antibodies (Basel). 2020;9(4).

548 32. Brandtzaeg P. Secretory immunity with special reference to the oral cavity. J Oral
549 Microbiol. 2013;5.

550 33. Ceron JJ, Lamy E, Martinez-Subiela S, Lopez-Jornet P, Capela ESF, Eckersall

551 PD, et al. Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A General

552 Perspective. J Clin Med. 2020;9(5).

553 34. Laxton CS, Peno C, Hahn AM, Allicock OM, Perniciaro S, Wyllie AL. The

554 potential of saliva as an accessible and sensitive sample type for the detection of

respiratory pathogens and host immunity. Lancet Microbe. 2023;4(10):e837-e50.

- 556 35. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claer L, et al. IgA dominates the
- early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13(577).







A

